Ursodeoxycholic acid "mechanisms of action and clinical use in hepatobiliary disorders"

Research output: Contribution to journalArticle

257 Citations (Scopus)

Abstract

UDCA exerts its beneficial effect in liver diseases through a diverse, probably, complementary array of mechanisms. The clinical use and efficacy of UDCA in PBC have been evident. UDCA may also have a place in the management of PSC, ICP, cystic fibrosis, PFIC and GVHD involving the liver, although, more studies are needed to further determine its therapeutic potential in these diseases and in other hepatobiliary disorders such as liver allograft rejection, drug and TPN-induced cholestasis, NASH, and alcoholic liver disease.

Original languageEnglish (US)
Pages (from-to)134-146
Number of pages13
JournalJournal of Hepatology
Volume35
Issue number1
DOIs
StatePublished - 2001

Fingerprint

Ursodeoxycholic Acid
Alcoholic Liver Diseases
Liver
Cholestasis
Cystic Fibrosis
Allografts
Liver Diseases
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Ursodeoxycholic acid "mechanisms of action and clinical use in hepatobiliary disorders". / Lazaridis, Konstantinos N; Gores, Gregory James; Lindor, Keith D.

In: Journal of Hepatology, Vol. 35, No. 1, 2001, p. 134-146.

Research output: Contribution to journalArticle

@article{dc873bca4cca49339414ba1edeb45221,
title = "Ursodeoxycholic acid {"}mechanisms of action and clinical use in hepatobiliary disorders{"}",
abstract = "UDCA exerts its beneficial effect in liver diseases through a diverse, probably, complementary array of mechanisms. The clinical use and efficacy of UDCA in PBC have been evident. UDCA may also have a place in the management of PSC, ICP, cystic fibrosis, PFIC and GVHD involving the liver, although, more studies are needed to further determine its therapeutic potential in these diseases and in other hepatobiliary disorders such as liver allograft rejection, drug and TPN-induced cholestasis, NASH, and alcoholic liver disease.",
author = "Lazaridis, {Konstantinos N} and Gores, {Gregory James} and Lindor, {Keith D.}",
year = "2001",
doi = "10.1016/S0168-8278(01)00092-7",
language = "English (US)",
volume = "35",
pages = "134--146",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Ursodeoxycholic acid "mechanisms of action and clinical use in hepatobiliary disorders"

AU - Lazaridis, Konstantinos N

AU - Gores, Gregory James

AU - Lindor, Keith D.

PY - 2001

Y1 - 2001

N2 - UDCA exerts its beneficial effect in liver diseases through a diverse, probably, complementary array of mechanisms. The clinical use and efficacy of UDCA in PBC have been evident. UDCA may also have a place in the management of PSC, ICP, cystic fibrosis, PFIC and GVHD involving the liver, although, more studies are needed to further determine its therapeutic potential in these diseases and in other hepatobiliary disorders such as liver allograft rejection, drug and TPN-induced cholestasis, NASH, and alcoholic liver disease.

AB - UDCA exerts its beneficial effect in liver diseases through a diverse, probably, complementary array of mechanisms. The clinical use and efficacy of UDCA in PBC have been evident. UDCA may also have a place in the management of PSC, ICP, cystic fibrosis, PFIC and GVHD involving the liver, although, more studies are needed to further determine its therapeutic potential in these diseases and in other hepatobiliary disorders such as liver allograft rejection, drug and TPN-induced cholestasis, NASH, and alcoholic liver disease.

UR - http://www.scopus.com/inward/record.url?scp=0034945397&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034945397&partnerID=8YFLogxK

U2 - 10.1016/S0168-8278(01)00092-7

DO - 10.1016/S0168-8278(01)00092-7

M3 - Article

VL - 35

SP - 134

EP - 146

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

IS - 1

ER -